Skip to main content
Immunocore Holdings plc logo

Immunocore Holdings plc — Investor Relations & Filings

Ticker · IMCR ISIN · US45258D1054 LEI · 213800IUE3DFS84BVN18 US Manufacturing
Open in API
Filings indexed 250 across all filing types
Latest filing 2026-05-27 Declaration of Voting R…
Country GB United Kingdom
Listing US IMCR

About Immunocore Holdings plc

https://www.immunocore.com/

Immunocore Holdings plc is a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies. Its proprietary ImmTAX (Immune mobilizing monoclonal TCRs against X disease) platform is designed to harness the body's immune system. The technology engineers TCRs to recognize and target diseased cells, making them visible for destruction by the immune system, or to suppress the immune system in autoimmune conditions. The company's diverse clinical pipeline targets a broad range of indications, including solid tumors, infectious diseases such as HIV and hepatitis B, and autoimmune disorders. Immunocore developed and commercialized the world's first approved TCR therapy.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K reporting Item 5.07, which provides the detailed vote counts for resolutions approved at the company’s Annual General Meeting of shareholders. It is not a financial report or a proxy statement itself, but the official announcement of voting results. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-27 English
S-8 - Immunocore Holdings plc (0001671927) (Filer)
Share Issue/Capital Change Classification · 89% confidence The document is a Registration Statement on Form S-8 under the Securities Act of 1933, registering additional ordinary shares under an equity incentive plan. It is not an annual report or earnings release but a filing to issue new shares under a share plan. This falls squarely under Share Issue/Capital Change (SHA).
2026-05-08 English
8-K - Immunocore Holdings plc (0001671927) (Filer)
Report Publication Announcement Classification · 85% confidence The document is a Form 8-K current report that merely furnishes a press release announcing first-quarter results (Item 2.02) and does not include substantive financial data itself. At under 5,000 characters, it fits the “report publication announcement” pattern (not the actual earnings release). Thus it should be classified as a Report Publication Announcement (RPA).
2026-05-06 English
10-Q - Immunocore Holdings plc (0001671927) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-06 English
8-K - IMMUNOCORE HOLDINGS PLC (0001671927) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 25, 2026, by Immunocore Holdings plc. It announces the issuance of a press release with financial results for the fourth quarter and full year ended December 31, 2025. The document itself does not contain the financial results but furnishes the press release as an exhibit. The text explicitly states that the information is being furnished and shall not be deemed "filed" for certain regulatory purposes, indicating this is an announcement of results rather than the results themselves. The document length is 4042 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this is an Earnings Release (ER) type document, which is the initial announcement of quarterly/periodical financial results (key highlights only).
2026-02-25 English
10-K - IMMUNOCORE HOLDINGS PLC (0001671927) (Filer)
Annual Report FY 2025
2026-02-25 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.